The things serious applicants ask first.

No. Many partners come from business rather than clinical backgrounds — diagnostics, pharmacy, or general entrepreneurship. What matters is that you intend to be an owner-operator. The clinical layer is provided: your technicians are trained and certified at the founding centre, the protocol is documented, and a central nephrology team stands behind every territory.

It depends which of the two models you run. A metropolitan (Tier A) territory takes approximately ₹36 lakh for the Home model, or approximately ₹55 lakh for Home + Wheels, which adds a fitted mobile unit. In both cases ₹15 lakh is the one-time franchise fee; the remainder is your own operating asset — equipment, opening stock and working capital — which stays on your books. Tiers B and C carry a lower fee.

The line-by-line breakdown and the investment calculator are on the Investment page, released once you have identified yourself and accepted our confidentiality terms.

Home delivers treatment in the patient’s own home. You buy no vehicle — the machine is moved by hired ambulance as and when a session requires it. It carries the higher price per session, because the setup is dedicated to that family.

Home + Wheels adds an ambulance fitted as a mobile dialysis unit, which serves several patients a day on a route. The price per session is lower, but the throughput is materially higher, and it reaches families a fixed home setup cannot practically serve. It is an additional market rather than the same patients at a discount.

The wheels model also carries its own fixed costs — two drivers, a nurse, fuel and vehicle upkeep — which the calculator on the Investment page sets out.

No. Whether you purchase or finance the mobile unit is entirely your decision and Diagnex takes no part in it. What we do approve is the fitted layout and the specification of the equipment inside it, because a Diagnex session runs to one standard wherever it is delivered.

Exclusive rights to operate home haemodialysis in a defined territory for 36 months, the clinical protocol library and standard operating procedures, technician training and certification, the Diagnex Core platform, central nephrology escalation, consumables supply through the group, launch marketing, and a Fresenius 4008S machine, supplied and commissioned through the group.

Patient acquisition is the partner's responsibility, supported by referral introductions through the group's clinical network. Those introductions are genuine support, but they are not a guarantee of patient numbers or revenue — the partner builds and owns the local patient relationships.

For the 36-month term, no other Diagnex operator competes inside your territory. Renewal is available and is linked to meeting agreed patient-milestone targets, so continued exclusivity reflects an active, growing operation.

Two reasons. It is the source of the structural cost advantage that protects your margin, and it is how the clinical standard is held consistent — the same validated consumables in every home, in every territory.

Through Diagnex Core. Every session is recorded and checked against the protocol, deviations are visible immediately, and escalation reaches a central nephrology team with the full record attached. Consistency across territories is the network's core product.

Typically the process runs from application to launch over roughly three months — the bulk of that being the discovery, agreement, installation and technician certification stages.

The franchise agreement sets out the terms for transfer and exit. Because the partner owns the operating assets and the local patient relationships, the operation is a genuine business rather than a licence — the specifics are covered in the agreement, shared during discovery.